Physician profile
Rahul M Kale
NPI 1447330915
$4,648.05
in general payments reported to CMS, 2019-2025
41 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $180 · 2022: $201 · 2023: $841 · 2024: $1,175 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.89 |
| Education | $164.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $784.87 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $354.97 | 2019-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $278.93 | 2022-2025 | |
| Genentech USA, INC. | $251.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.25 | 2019-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $237.81 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $229.55 | 2022-2024 | Cuvitru, Glassia, Hyqvia |
| Grifols USA, LLC | $204.26 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $197.31 | 2020-2025 | Arikayce |
| Mylan Specialty L.P. | $173.26 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $172.62 | 2022-2025 | Zepbound, Mounjaro, Trulicity |
| Sanofi-Aventis U.S. LLC | $147.47 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $136.56 | 2019-2025 | Dupixent |
| Axsome Therapeutics, INC. | $112.45 | 2024-2025 | Sunosi |
| Vifor Pharma, INC. | $101.30 | 2024-2025 | Zemaira |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $80.62 | 2024-2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $80.55 | 2024-2025 | Lumryz |
| Philips North America LLC | $77.78 | 2019-2025 | Dreamwear 7200 Sp Mask |
| Abbvie INC. | $70.51 | 2022-2023 | |
| Verona Pharma, INC. | $66.56 | 2025 | Ohtuvayre |
| Baxter Healthcare | $63.74 | 2023 | Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $61.23 | 2019-2025 | |
| Sanofi Pasteur INC. | $50.40 | 2019-2025 | |
| United Therapeutics Corporation | $48.49 | 2023-2024 | Tyvaso |
| Intuitive Surgical, INC. | $36.65 | 2024 | |
| Ani Pharmaceuticals, INC. | $33.57 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $33.29 | 2019-2020 | |
| Harmony Biosciences LLC | $32.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.49 | 2025 | Rexulti |
| Shire North American Group INC | $30.62 | 2019 | |
| Fisher & Paykel Healthcare INC | $30.26 | 2023 | Fisher & Paykel Healthcare |
| Mallinckrodt Hospital Products INC. | $26.85 | 2020 | |
| 3b Medical, INC. | $26.53 | 2025 | Luna |
| Exact Sciences Corporation | $22.78 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.15 | 2023 | Xifaxan |
| Almatica Pharma LLC | $17.65 | 2023 | Gralise, Loreev Xr |
| Novo Nordisk INC | $17.46 | 2024 | Wegovy |
| Pulmonx Corporation | $14.63 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Merck Sharp & Dohme LLC | $14.12 | 2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $13.20 | 2019 | |
| Endogastric Solutions, INC | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Kale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.